MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors.



Status:Recruiting
Healthy:No
Age Range:18 - 99
Updated:12/7/2018
Start Date:March 21, 2017
End Date:August 15, 2022
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination With Durvalumab in Selected Advanced Solid Tumors

The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and
antitumor activity in adult subjects with selected advanced solid tumor malignancies

This is a global Phase 1, first-time-in-human, multicenter, open-label, dose-escalation and
dose-expansion study of MEDI5083 alone and in combination with durvalumab

Inclusion Criteria:

1. Age ≥ 18 years at the time of screening or age of consent according to local law

2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

3. Histologically or cytologically confirmed metastatic or recurrent tumor types

4. Subjects who have received prior immunotherapy may be eligible

5. Subjects must have at least one measurable lesion

6. Consent to provide archival tumor tissue and pre/on-treatment biopsies

7. Adequate organ and marrow function

8. Consent to use one highly effective method of contraception

Exclusion Criteria:

1. Receipt of any systemic anticancer therapy within 28 days prior to the first dose of
MEDI5083

2. Concurrent enrollment in another clinical study

3. Active/prior autoimmune of inflammatory disorders

4. History of immunodeficiency, solid organ transplant, or tuberculosis

5. Known allergy/hypersensitivity to drug or components

6. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or
cord compression

7. Current or prior use of immunosuppressive medication within 14 days prior to the first
dose of MEDI5083
We found this trial at
6
sites
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Clayton,
Click here to add this to my saved trials
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Providence, RI
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials